18.55
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 - GlobeNewswire
What the charts say about Zymeworks Inc. todayJuly 2025 Volume & Community Consensus Stock Picks - newser.com
JPM places Zymeworks on positive catalyst watch ahead of ZW191 Phase 1 data - Investing.com
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade - sharewise.com
JPMorgan Chase & Co. Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price - MarketBeat
What is HC Wainwright's Forecast for Zymeworks Q3 Earnings? - MarketBeat
Zymeworks to Announce Q3 2025 Financial Results and Host Conference Call - TipRanks
Zymeworks Inc. to Report Q3 2025 Financial Results and Host Conference Call on November 6, 2025 - Quiver Quantitative
Applying Elliott Wave Theory to Zymeworks Inc.Gold Moves & AI Enhanced Trading Alerts - newser.com
Zymeworks, Inc. Hits New 52-Week High of USD 19.50 - Markets Mojo
Will Zymeworks Inc. stock attract ESG investors2025 Earnings Surprises & Safe Entry Momentum Tips - newser.com
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's Why - MarketBeat
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
HC Wainwright & Co. Upgrades Zymeworks (ZYME) - Nasdaq
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Will Zymeworks Inc. stock sustain high P E ratios2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
How Zymeworks Inc. stock compares to market leadersJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - newser.com
Will Zymeworks Inc. stock outperform growth indexesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Zymeworks to present early data on ZW191 cancer drug at conference - Investing.com Nigeria
Zymeworks to present early data on ZW191 cancer drug at conference By Investing.com - Investing.com South Africa
Zymeworks Presents Preliminary Phase 1 Results for ZW191 Targeting Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference - The Manila Times
Zymeworks to Present Clinical Data from the Phase 1 trial - GlobeNewswire
Phase 1 preliminary data: ZW191 (FRα-targeting ADC) — Zymeworks to present at AACR Oct 23 - Stock Titan
Using economic indicators to assess Zymeworks Inc. potentialOptions Play & Community Consensus Picks - newser.com
What technical models suggest about Zymeworks Inc.’s comebackQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
Zymeworks (ZYME): Evaluating Valuation Following New Leadership and Key Regulatory Wins - Sahm
Is Zymeworks Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy? - Yahoo
Zymeworks (NYSE:ZYME) Stock Price Up 7.2%Here's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 17.71 USD By Investing.com - Investing.com Canada
How Might ZYME’s Shifting Leadership Shape Its Late-Stage Oncology Ambitions? - simplywall.st
B. Riley Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks stock hits 52-week high at 17.71 USD - Investing.com
Zymeworks (ZYME) Coverage Initiated by B. Riley Securities with 'Buy' Rating | ZYME Stock News - GuruFocus
Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks appoints Adam Schayowitz as acting chief development officer By Investing.com - Investing.com Nigeria
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements - TipRanks
Zymeworks appoints Adam Schayowitz as acting chief development officer - Investing.com India
Zymeworks Inc. Appoints Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer - Quiver Quantitative
Adam Schayowitz named Acting CDO at Zymeworks to advance clinical R&D and partnerships — Oct. 9, 2025 - Stock Titan
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):